<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82146">
  <stage>Registered</stage>
  <submitdate>10/07/2007</submitdate>
  <approvaldate>12/07/2007</approvaldate>
  <actrnumber>ACTRN12607000366459</actrnumber>
  <trial_identification>
    <studytitle>Study of Acquired Viral Mutations in Chronic Hepatitis B Patients on Antihepadnaviral Therapy</studytitle>
    <scientifictitle>An Observational Study of Acquired Viral Mutations in Chronic Hepatitis B Patients on Antihepadnaviral Therapy.</scientifictitle>
    <utrn />
    <trialacronym>CHARM</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Hepatitis B</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Liver</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Non-Interventional</interventions>
    <comparator>No comparator</comparator>
    <control>Uncontrolled</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>A description of the prevalence and nature of hepatitis B virus mutations detectable in subjects managed in the naturalistic setting in Australia</outcome>
      <timepoint>At the time of recruitment into the study.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Investigate relationships between demographic, and retrospective clinical (including treatment) related factors and the detection of specific viral mutation profiles at the time of enrolment.</outcome>
      <timepoint>At the time of enrolment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Establish the lower limit if hepatitis B viral load at which deoxyribonucleic acid (DNA) sequence analysis of the catalytic region of the hepatitis B virus polymerase (encoding amino acids 1-257 and 75-257) can be performed.</outcome>
      <timepoint>Analysis will be carried out at one single time-point</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Provided informed consent-Diagnosis of chronic hepatitis B (HBsAg documented for at least 6 months)-Currently prescribed antihepadnaviral therapy (including, but not limited to: lamivudine, adefovir, entecavir, tenofovir or telbivudine) for chronic hepatitis B management-Been taking current antihepadnaviral therapy for at least 6 months prior to recruitment-Negative tests for HIV Ab, Hepatitis C Ab and Hepatitis D Ab within the previous 2 yearsKey</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known or suspected co-infection with HIV, Hepatitis C or Hepatitis D-Concomitant immunosuppression / immunomodulator therapies-Diagnosis of hepatocellular carcinoma where anticipated life expectancy is less than 6 months-Current participation in an interventional, blinded, pharmaceutical industry-sponsored clinical trial -Current Child Pugh class C classification (current Child Pugh score &gt; 9)-Other known or suspected cause of chronic liver disease-Any other reason that, in the investigators opinion, participation in the study would not be in the participants best interest.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Both</timing>
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/08/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>800</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences Pty Ltd</primarysponsorname>
    <primarysponsoraddress>Gilead Sciences Pty Ltd Level 1 128 Jolimont Road East Melbourne VIC 3002</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Gilead Sciences Pty Ltd</fundingname>
      <fundingaddress>Gilead Sciences Pty Ltd Level 1 128 Jolimont Road East Melbourne VIC 3002</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Clinical experience has shown continued use of antiviral medication to treat hepatitis B can lead to changes or mutations in the hepatitis B virus (or HBV). The virus, once it has mutated, might then be resistant to the particular medication previously taken, and a new hepatitis B medication is needed to mange the infection. If the infection is not managed with effective medication liver damage can occur. Early detection of hepatitis B mutations can enable doctors to manage hepatitis B treatment before further liver damage can occur.

The purpose of this project is to describe the mutations in the hepatitis B virus in Australian patients with hepatitis B. Further, it aims to investigate the relationships between demographic and clinical factors to the appearance of these viral mutations.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Amanda Elsome</name>
      <address>Gilead Sciences Pty Ltd
Level 1
128 Jolimont Road
East Melbourne VIC 3002</address>
      <phone>+61 3 9272 4433</phone>
      <fax>+61 3 9272 4435</fax>
      <email>amanda.elsome@gilead.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Amanda Elsome</name>
      <address>Gilead Sciences Pty Ltd
Level 1, 128 Jolimont Road
East Melbourne VIC 3002</address>
      <phone>+61 3 9272 4433</phone>
      <fax>+61 3 9272 4435</fax>
      <email>amanda.elsome@gilead.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kim Mitchell</name>
      <address>Gilead Sciences Pty Ltd Level 1 128 Jolimont Road East Melbourne VIC 3002</address>
      <phone>+61 3 9272 4469</phone>
      <fax>+61 3 9272 4435</fax>
      <email>kim.mitchell@gilead.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>